C4 Therapeutics
CCCC
83 hedge funds and large institutions have $64.5M invested in C4 Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 23 closing their positions.
0.42% more ownership
Funds ownership: 69.76% → 70.18% (+0.42%)
6% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 32
17% less funds holding
Funds holding: 100 → 83 (-17)
20% less call options, than puts
Call options by funds: $24K | Put options by funds: $30K
31% less capital invested
Capital invested by funds: $94.1M → $64.5M (-$29.6M)
70% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$6.3M |
| 2 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$3.75M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$3.11M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.65M |
| 5 |
M&T Bank
Buffalo,
New York
|
+$427K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.95M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$2.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.96M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$858K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$840K |
CCCC Hedge Fund Activity: Q3 2023 in Review
83 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q3 2023, worth a combined $64.5M — down 31% from $94.1M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of CCCC and 7 opened new positions — a net loss of 16 holders — while 32 trimmed existing stakes and 30 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $6.3M. The largest seller was Millennium Management, cutting an estimated $2.95M.
- 83 institutional investors held C4 Therapeutics (CCCC) as of Q3 2023, down from 100 in Q2 2023.
- Funds reported $64.5M of C4 Therapeutics stock for Q3 2023, down 31% quarter-over-quarter.
- 7 funds opened new C4 Therapeutics positions in Q3 2023 and 23 closed out, a net change of -16 holders.
- The largest C4 Therapeutics buyer in Q3 2023 was ArrowMark Colorado Holdings, an estimated $6.3M added.
- The largest C4 Therapeutics seller in Q3 2023 was Millennium Management, an estimated $2.95M sold.
Based on aggregated 13F filings for Q3 2023.